TVB-3567
Acne Vulgaris
Phase 1First-in-human trial initiated June 2025
Key Facts
Indication
Acne Vulgaris
Phase
Phase 1
Status
First-in-human trial initiated June 2025
Company
About Sagimet Biosciences
Sagimet Biosciences is advancing a novel therapeutic platform centered on the selective inhibition of Fatty Acid Synthase (FASN), a key enzyme in the dysfunctional de novo lipogenesis pathway. The company's lead asset, denifanstat, has achieved critical milestones, including positive Phase 2b biopsy data in MASH (FASCINATE-2), Breakthrough Therapy designation from the FDA, and successful Phase 3 results in acne from a partner-led trial. With a seasoned leadership team and a clear path to Phase 3 in MASH, Sagimet's strategy is to develop first-in-class oral therapies for diseases driven by lipotoxicity, including MASH, acne, and select cancers.
View full company profileTherapeutic Areas
Other Acne Vulgaris Drugs
| Drug | Company | Phase |
|---|---|---|
| Encube-002 | Encube Ethicals | Preclinical |
| Pipeline Program | MatriSys Bioscience | Preclinical |
| AKVANO®-based Acne treatment | Lipidor | Pre-clinical/Phase 1 |
| Acne & Impure Skin | Pelpharma Handels | Commercial |
| GM-503 | Galderma Group | Phase 1 |
| CB-03-01 (Cortexolone 17α-propionate) | Cosmo Pharmaceuticals | Phase III |
| TWYNEO® (tretinoin/BPO) | Sol-Gel Technologies | Commercial |
| SGT-510 | Sol-Gel Technologies | Phase 2 |
| TWYNEO® | Mayne Pharma Group | Marketed |